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Abstract
Background: It has previously been shown that specific microdeletions and microduplications,
many of which also associated with cognitive impairment (CI), can present with autism spectrum
disorders (ASDs). Multiplex ligation-dependent probe amplification (MLPA) represents an efficient
method to screen for such recurrent microdeletions and microduplications.
Methods: In the current study, a total of 279 unrelated subjects ascertained for ASDs were
screened for genomic disorders associated with CI using MLPA. Fluorescence in situ hybridization
(FISH), quantitative polymerase chain reaction (Q-PCR) and/or direct DNA sequencing were used
to validate potential microdeletions and microduplications. Methylation-sensitive MLPA was used
to characterize individuals with duplications in the Prader-Willi/Angelman (PWA) region.
Results: MLPA showed two subjects with typical ASD-associated interstitial duplications of the
15q11-q13 PWA region of maternal origin. Two additional subjects showed smaller, de novo
duplications of the PWA region that had not been previously characterized. Genes in these two
novel duplications include GABRB3 and ATP10A in one case, and MKRN3, MAGEL2 and NDN in the
other. In addition, two subjects showed duplications of the 22q11/DiGeorge syndrome region. One
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individual was found to carry a 12 kb deletion in one copy of the ASPA gene on 17p13, which when
mutated in both alleles leads to Canavan disease. Two subjects showed partial duplication of the
TM4SF2 gene on Xp11.4, previously implicated in X-linked non-specific mental retardation, but in
our subsequent analyses such variants were also found in controls. A partial duplication in the ASMT
gene, located in the pseudoautosomal region 1 (PAR1) of the sex chromosomes and previously
suggested to be involved in ASD susceptibility, was observed in 6–7% of the cases but in only 2%
of controls (P = 0.003).
Conclusion: MLPA proves to be an efficient method to screen for chromosomal abnormalities.
We identified duplications in 15q11-q13 and in 22q11, including new de novo small duplications, as
likely contributing to ASD in the current sample by increasing liability and/or exacerbating
symptoms. Our data indicate that duplications in TM4SF2 are not associated with the phenotype
given their presence in controls. The results in PAR1/PAR2 are the first large-scale studies of gene
dosage in these regions, and the findings at the ASMT locus indicate that further studies of the
duplication of the ASMT gene are needed in order to gain insight into its potential involvement in
ASD. Our studies also identify some limitations of MLPA, where single base changes in probe
binding sequences alter results. In summary, our studies indicate that MLPA, with a focus on
accepted medical genetic conditions, may be an inexpensive method for detection of
microdeletions and microduplications in ASD patients for purposes of genetic counselling if MLPA-
identified deletions are validated by additional methods.
Background
Autism spectrum disorders (ASDs) are pervasive develop-
mental disorders that include autism, Asperger syndrome,
and pervasive developmental disorder-not otherwise
specified (PDD-NOS). ASDs are characterized by varying
degrees of impairment in communication and social
interactions, as well as by the presence of restricted, repet-
itive and/or stereotyped patterns of behavior, interests,
and/or activities, with signs typically manifesting by the
age of 3. Recent epidemiological studies report a preva-
lence of ASD of 3–6 per 1000 children [1,2]. Males have a
higher risk than females, with a male to female ratio of
~4:1. Twin studies show a concordance rate of 60%–90%
for monozygotic twins and 0–10% for dizygotic twins,
and the genetic liability for autism is estimated to be more
than 90% [3]. In spite of the high heritability, the identi-
fication of genetic factors in ASDs has proved difficult,
due at least in part to the fact that ASDs are characterized
by a high degree of genetic heterogeneity.
In the past, approximately 10% of individuals with ASDs
could be diagnosed as having secondary autism, in which
a chromosome abnormality, single-gene disorder, or
known environmental agent was identified as causative
[3,4]. However, more recent studies suggest that chromo-
some abnormalities and single-gene disorders are more
common as causes of ASDs [5,6]. Many children with ASD
have some degree of cognitive impairment (CI) and
genetic disorders associated with CI have also been asso-
ciated with ASDs. Thus, ASDs have been reported as pos-
sible manifestations of genetic syndromes resulting in CI,
including fragile X syndrome, tuberous sclerosis, Angel-
man syndrome, Prader-Willi syndrome, 22q11 deletion/
DiGeorge syndrome, Cohen syndrome, Smith-Lemli-
Opitz syndrome, Smith-Magenis syndrome, Williams syn-
drome, Sotos syndrome, and Klinefelter syndrome [7-10].
Chromosomal abnormalities throughout the genome
have been reported in cases of ASD [11]. In addition to
traditional methods like FISH to detect chromosome
abnormalities, new array-based techniques allow robust
whole genome scanning for copy number variants (CNVs)
and have resulted in the identification of new disease
genes [12-14]. For example, using Affymetrix 10 K SNP
arrays, the Autism Genome Project Consortium identified
deletions in the neurexin 1 gene (NRXN1) in 2p16 as a
cause for ASD [15], now described in further studies
[13,16,17]. More recently several groups have reported
deletions in 16p11 in ASD [13,14,18]. Multiplex ligation-
dependent probe amplification (MLPA) is a recently
developed method to accurately quantify levels of diverse
DNA sequences based on target-directed ligation followed
by quantitative polymerase chain reaction (Q-PCR), and
can be used to test for the presence of chromosomal
abnormalities that lead to changes in copy number. For
each sequence of interest, the two probes are joined by the
use of a ligase only if they are both bound to a specified
target sequence. The resultant ligated product is then
amplified by Q-PCR in a manner proportional to the ini-
tial levels. MLPA has been proposed as a rapid and cost-
effective method for routine screen of chromosome
abnormalities in mental retardation [19,20]. To deter-
mine the degree to which chromosome abnormalities
associated with CI contribute to autism, and to evaluate
MLPA for genetic counselling, 279 unrelated ASD subjects
were screened for CI-associated deletions using MLPA.BMC Medical Genomics 2008, 1:50 http://www.biomedcentral.com/1755-8794/1/50
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Methods
Subjects
A total of 279 unrelated individuals with an autism or
autism spectrum diagnosis were recruited by the Seaver
Autism Research Center (SARC) and/or the Autism
Genetic Resources Exchange (AGRE). All parents provided
written informed consent. Affected status conformed to
the following categories, used by AGRE and by other
researchers: autism, not quite autism, and broad spec-
trum. Individuals who met Autism Diagnostic Interview-
Revised (ADI-R) criteria for autism were categorized as
autism [21-23]. The term 'not quite autism' refers to indi-
viduals who are no more than one point away from meet-
ing autism criteria according to the ADI-R on any or all of
the 3 content domains (social, communication, and/or
behaviour) and meet the age of onset criterion (before 36
months); or individuals who meet criteria on all 3
domains, but do not meet criteria for age of onset. The
term 'broad spectrum' defines individuals who show pat-
terns of impairment along the spectrum of pervasive
developmental disorders, which encompasses individuals
ranging from mildly- to severely- impaired. Given this
broad classification and as there was in many cases suffi-
cient clinical information to assign a diagnosis of perva-
sive developmental disorder-not otherwise specified
(PDD-NOS) or Asperger disorder (based on DSM-IV crite-
ria) to some of these individuals, these classifications are
also enumerated. Subjects had been previously subjected
to a routine work-up to exclude medical conditions,
including major chromosomal abnormalities, as well as
fragile X syndrome and tuberous sclerosis. Subjects with
such abnormalities were excluded from the current study.
The 279 individuals screened included 254 from multiple
affected (multiplex) families, and 25 from singly affected
(simplex) families. The sex distribution in the sample was
3.9 males to 1 female (222:57). Within the sample, 205
were self-identified as Caucasian, 6 African American, 24
Hispanic or Latino, 5 Asian, and 11 of mixed ethnicity,
with 28 of an unknown ethnicity. There were 270 subjects
with a diagnosis of autism, 2 with Asperger syndrome, 1
with PDD-NOS, 3 with NQA and 3 with broad spectrum
diagnoses. Average age at last evaluation was 7.94 ± 5.79
years old. Amongst ninety subjects evaluated for IQ with
the Raven, sixteen (17.8%) had IQ scores below 70 and 10
(11.1%) had scores between 70–79. When an abnormal
MLPA probe signal was observed, all available family
members were included in subsequent analyses. All stud-
ies were approved by the Program for the Protection of
Human Subjects of Mount Sinai School of Medicine
(GCO#06-0688).
MLPA
MLPA probe sets targeting chromosomal regions previ-
ously associated with CI were purchased from MRC-Hol-
land (Amsterdam, Netherlands) and used according to
the manufacturer's protocols. Briefly, 50–200 ng genomic
DNA in 5 μl water was denatured, mixed with a probe set
(SALSA MLPA Kits P064-MR1, P096-MR2, P106-MRX, or
P018-SHOX) and high salt MLPA buffer. The mixture was
hybridized at 60°C for 16 h. The ligation reaction was
then performed and 5 μl of the ligation reaction product
was used for PCR. Subsequently, PCR products were sub-
jected to capillary electrophoresis on an ABI 3130 genetic
analyzer (Applied Biosystem, Foster City, CA, USA). Raw
traces from the electrophoresis were imported into Gene-
Marker software (SoftGenetics, State College, PA, USA) for
MLPA analysis. After population normalization, data were
compared to two different controls: 1) a single control
sample, representing the sample with the fewest abnormal
calls in each experiment; and, 2) a synthetic control sam-
ple, which represents the median of all normal samples in
each experiment. A threshold of dosage change <0.75 was
used to identify potential deletions, and a threshold >1.30
was used to identify potential duplications. All samples
with potential deletions or duplications were re-analyzed
by MLPA. To analyze the 15q11-q13 interval, a methyla-
tion-specific multiplex ligation-dependent probe amplifi-
cation (MS-MLPA) kit (SALSA MLPA kit ME028 PWS/AS,
from MRC-Holland) was used. This kit contains 12 meth-
ylation-sensitive probes in 15q11-q13, of which 5 are sub-
ject to imprinting, as well as 3 methylation-sensitive
probes in other regions.
FISH
Commercially available locus specific probes, TUPLE1
(22q11.2), D15S11 (15q11.2), SNRPN (15q11.2), and
GABRB3 (15q11.2) were purchased from Vysis (IL). BAC
DNAs for validation of MLPA results were obtained
directly from BAC PAC resources (CA). Each BAC was
labelled using the Nick Translation Reaction Kit and Spec-
trum Green-11-dUTP (Vysis, IL, USA). Single coloured
FISH was performed on metaphase spreads and inter-
phase nuclei from established lymphoblastoid lines
dropped onto pre-cleaned glass slides. Co-denaturation
and hybridization of probes and slides was performed at
73°C for 3 minutes and 37°C overnight, respectively,
using the HyBrite hybridization system (Vysis, IL, USA).
After hybridization and washing, chromosomes and
nuclei were counterstained with 0.5 μg/ml DAPI (4',6-
Diamidino-2-Phenylindole Dihydrochloride) in Vectash-
ield (Vector Laboratories, CA, USA) and a cover slip was
applied to the slide. Images were captured with an Image-
Point cooled CCD video camera (Photometrics, AZ, USA)
through a Labophot-2A florescence microscope (Nikon,
NY, USA) using Cytovision FISH software (Applied Imag-
ing, CA, USA). Generally, 3 to 5 metaphases were exam-
ined and 50 – 100 interphase nuclei were scored for the
number of signals present for each probe.BMC Medical Genomics 2008, 1:50 http://www.biomedcentral.com/1755-8794/1/50
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Q-PCR and Direct Sequencing
Validation of samples with apparent deletions/duplica-
tions included direct sequencing, Q-PCR and/or fluores-
cent in situ hybridization (FISH). Genomic Q-PCR using
the Universal Probe Library (UPL) probe (Roche, IN,
USA) was performed to confirm microdeletions or micro-
duplications. Probes were selected using the ProbeFinder
v2.04 software (Roche, IN, USA). Quantitative PCR was
performed on an ABI Prism™ 7900 HT sequence detection
system (Applied Biosystems, CA, USA). Each sample was
analyzed in quadruplicate in a reaction including 25 ng
genomic DNA, 200 nM of each primer, 100 nM UPL
probe, and 1× Platinum Quantitative PCR SuperMix-
Uracil-N-Glycosylase (UDG) with ROX (Invitrogen, CA,
USA). The values were evaluated using the Sequence
Detection Software v2.1 (Applied Biosystems, CA, USA).
Data analysis was performed using qBase [23]. Reference
genes chosen from COBL, GUSB, PPIA, SNCA were
included based on the minimal coefficient of variation
and then data was normalized by setting a normal control
to a value of 1.
Results
We made use of four commercial MLPA panels (MR1,
MR2, MRX, and SHOX, which included 84 probes
directed at autosomal loci and 46 probes directed at X-
linked loci, 4 probes at Y-linked loci, and 27 probes
directed at PAR1/PAR2), covering many of the chromo-
somal regions associated with known, recurrent dele-
tions/duplications associated with CI [see Additional file
1].
MLPA screening identified increased or decreased signal
in 28 subjects out of the 279 screened, consistent with
potential microduplications or microdeletions. We
observed potential duplications in 15q11-q13 (4 sub-
jects), 22q11 (2 subjects), the TM4SF2 gene in Xp11 (2
subjects), and the ASMT gene in Xp22.32 (PAR1) (16 sub-
jects). We observed potential deletions in the ASPA gene
in 17p13 (1 subject), the PAX6 gene in 11p13 (1 subject),
the EXT1 gene in 8q24 (1 subject), and the ARHGEF6 gene
in Xq26 (1 subject).
Copy number variation in 15q11.1-q13
The most common, autosomal, potential CNV observed
by MLPA was variation in the 15q11-q13 region, where
four unrelated probands demonstrated apparent duplica-
tions (Figure 1A, B, C) [clinical information is summa-
rized in Additional file 2]. This region, previously
associated with PWA and ASDs, was covered by four
probes, one each in the TUBGCP5, MKRN3, NDN and
GABRB3  genes. Probands 1 (AU010604) and 2
(AU023304) showed duplications in all probes, proband
3 (AU038504) had a duplication in the probe in GABRB3,
and proband 4 (AU013203) had a duplication in the
probes in MKRN3 and NDN.
Two common FISH probes, D15S11 and GABRB3, were
used to validate the duplications. Probands 1 and 2
showed duplications with both FISH probes, proband 3
showed duplication with the GABRB3 FISH probe but not
the D15S11 probe, and proband 4 did not show duplica-
tion with either FISH probe (data not shown). Proband 4
also showed normal hybridization with the NDN FISH
probe RP11-494F2, suggesting that the duplication might
be too small to be identified by FISH.
To further evaluate these duplications, 21 additional
MLPA probes within the 15q11-q13 region were used; the
additional probes were directed to CYFIP1  (1 probe),
MKRN3 (1 probe), MAGEL2 (2 probes), NDN (1 probes),
SNRPN  (6 probes), UBE3A  (4 probes), ATP10A  (2
probes),  GABRB3  (1 probe), OCA2  (2 probes), and
APBA2  (1 probe). Probands 1 and 2 showed signal
increases with all of these probes except for the probe in
APBA2  (Figure 1B), indicating that the duplication
included a 5.7 Mb region comprised between breakpoints
1 and 3 [24,25]. Proband 3 showed increases only for the
probes in ATP10A and GABRB3, encompassing a 1 Mb
region. Finally, proband 4 showed increases only for the
probes in MKRN3, MAGEL2 and NDN, encompassing a
limited region of 120 kb.
We next examined how these confirmed duplications seg-
regated in the families. In the family of proband 1 (Family
1), the duplication was maternally inherited, and was also
found in an affected brother. In Family 2, the proband
had a brother and a sister – both with a broad spectrum
diagnosis, with the sister, but not the brother, carrying the
duplication. The father and an unaffected brother did not
harbor the duplication, while the mother's DNA was not
available. In Family 3, the duplication was not found in
an affected sister or in either parent. Confirmation of
paternity and maternity by genotyping microsatellite
markers indicated that the duplication likely arose de novo.
In Family 4, the duplication was found in the affected,
monozygotic twin, but in neither parent. Again, confirma-
tion of paternity and maternity indicated that the duplica-
tion likely arose de novo.
We subsequently used methylation-sensitive MLPA to fur-
ther characterize these rearrangements. These analyses
confirmed that the duplication in the two affected chil-
dren in Family 1 was of maternal origin. In contrast, the
origin of the duplication in the mother is paternal, con-
sistent with an absence of phenotype in her. Methylation
analysis in children in Family 2 demonstrated a maternal
origin. For Family 3, neither the ATP10A nor GABRB3
probes are methylation-sensitive, so the analysis couldBMC Medical Genomics 2008, 1:50 http://www.biomedcentral.com/1755-8794/1/50
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not provide further data. Analysis in Family 4 demon-
strated the de novo duplication of the NDN  gene was
maternally-derived.
Copy number variation in 22q11.2
Two cases (probands 5-AU001804 and 6-AU004903)
with an apparent duplication in 22q11.2 were observed in
this study (Figure 2A, D) [see Additional file 2]. In both
cases, all three probes that were screened in the region (in
HIRA, CLDN5 and SNAP29) were duplicated (Figure 2B).
FISH analysis was used to confirm the duplications (Fig-
ure 2C) using a commercial test probe (TUPLE1, Vysis),
two additional test probes (b186O8 and p901P22) within
the duplication, one probe (b36N5) (data not shown) to
define the distal breakpoint and one control probe (ARSA,
Vysis) in 22q13. All three test probes (TUPLE1, b186O8
and p901P22) were clearly triplicated, demonstrating a
duplication in 22q11.2 with a direct orientation, corre-
sponding to the longer (3 Mb) of the two recurrent CNVs
observed in this region [26].
Examination of other family members indicated that in
Family 5, the duplication was inherited from the father,
but a brother, with a diagnosis of broad spectrum, did not
have the duplication. In Family 6, the proband, a girl with
a diagnosis of autism carried the duplication, but an
affected brother did not. Furthermore, the duplication
was not observed in either parent. Confirmation of pater-
Chromosome 15q11-q13 duplications in four families Figure 1
Chromosome 15q11-q13 duplications in four families. A. Schematic representation of the region, highlighting the extent 
of the duplications in the four families (blue lines), the localization of the MLPA probes (red triangles) and FISH probes (yellow 
ovals) used, and the genes within the interval along with their orientation (green arrows). B. MLPA peak ratio for 15q11-13 
(red and green) and control (blue) MLPA test probes in Family 1 individuals AU010604 (left) and AU010602 (right). Red, 
probes with peak ratios > 1.3; green, probes with peak ratios <= 1.3. In the left panel, the green rectangle with a peak ratio of 
~1 corresponds to APBA2. C. Segregation of the duplications in the four families.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Broad spectrum 
Autism 
NDN 
Family 3 
Family 1 and Family 2 
cen 
1 Mb 
D15S11  GABRB3 
tel 
 
TUBGCP5 
CYFIP1 
MKRN3 
MAGEL2 
NDN SNRPN  UBE3A  ATP10A  GABRB3  OCA2  APBA2 
MLPA probe 
FISH probe  Family 4 
Family 1 
dup 
dup  dup 
AU010604 
AU010601 
AU010603 
AU010602 
Family 2 
dup  dup 
AU023304  AU023303  AU023306 AU023305 
AU023302 
AU039505 
Family 3 
dup 
AU038504 AU038503 
HI038502 AU038501 
AU013203 
Family 4 
dup dup 
AU013204 AU013205 
AU013202 AU013201 
 
A 
B 
C BMC Medical Genomics 2008, 1:50 http://www.biomedcentral.com/1755-8794/1/50
Page 6 of 14
(page number not for citation purposes)
nity and maternity by microsatellite markers indicated
that the duplication likely arose de novo.
Additional copy number variation in an autosomal locus
One additional locus showed validated copy number
changes in the autosomes. Seven probes were screened in
the region associated with Miller-Dieker lissencephaly
syndrome and Canavan disease in 17p13-pter, in HIC1,
MGC3329, PAFAH1B1, ASPA, and TRPV1. In a boy with a
diagnosis of autism, we observed an apparent deletion in
a probe within the ASPA gene involved in Canavan dis-
ease. The apparent deletion was also observed in the boy's
monozygotic twin, and was maternally inherited. Q-PCR
analysis confirmed the presence of a 12.1 Kb deletion,
encompassing part of intron 3 and extending through
exon 5, on one allele of the ASPA gene. Sequencing the
second allele did not identify any coding abnormalities,
indicating that the boys were not compound heterozy-
gotes for coding variants.
Copy number variations in X-linked loci
Of the 77 probes directed to the sex chromosomes, 2, in
TM4SF2 and in ASMT, showed copy number changes.
A girl with a diagnosis of broad spectrum (proband 7-
AU038703) and an unrelated boy (proband 8-
AU032904) with a diagnosis of autism were found to
have an apparent duplication for a single probe (out of 2)
Chromosome 22q11 duplication in two families Figure 2
Chromosome 22q11 duplication in two families. A. Schematic representation of the region, highlighting the extent of 
the duplications in the two families (blue line), the localization of the MLPA probes (red triangles) and FISH probes (yellow 
ovals) used, and the genes within the interval along with their orientation (green arrows). B. MLPA peak ratio for 22q11 MLPA 
test probes in Family 5 individual AU001804. Red, probes with peak ratios > 1.3, corresponding to HIRA, CLDN5 and SNAP29; 
green, probes with peak ratios <= 1.3.C. FISH results of the 22q11 duplication. a, test probe TUPLE1 (red) in 22q11 shows 
three copies, whereas the control probe ARSA (green) in 22q13 shows two copies. b, both test probes b186O8 (green) and 
p901P22 (red) in 22q11 show three copies. D. Segregation of the duplication in the two families.
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in the X-linked gene TM4SF2  (Figure 3). The probe
mapped to exon 5 of the gene, while the probe showing
no apparent change was 114 kb away, on exon 1. In the
case of the girl, the duplication was maternally derived,
and was also found in an unaffected sister, but not in an
affected brother, while in the case of the boy the apparent
duplication was found in an affected sister, and was also
maternally derived. Genomic Q-PCR using the Universal
Probe Library (UPL) probe was performed to further char-
acterize the duplication. The TM4SF2 gene is comprised of
8 exons, with exon 1 — containing the ATG — followed
by a 104 kb intron, with the remaining exons and introns
covering an additional 23 kb region. UPL probes of the
TM4SF2 gene, located in the promoter, 480 bp before
exon 1, one each in exons 2, 3, 4, and 5, and two in the 3'
UTR (exon 8), and one probe 2422 bp down stream to the
gene, were tested (a probe in exon 1 was also tested, but it
failed in Q-PCR). All probes showed increased dosage
change, except the probe in the promoter, in agreement
with the MLPA results.
As it remained uncertain as to whether a duplication in
TM4SF2 represented a risk factor for CI (see Discussion),
we carried out genomic Q-PCR in 248 (174 males and 74
female) Caucasian controls (both ASD families carrying
the TM4SF2 duplication were of Caucasian ancestry). We
identified the duplication in 2 male and 4 female con-
Partial duplication of X-linked TM4SF2 gene in Xp11.4 Figure 3
Partial duplication of X-linked TM4SF2 gene in Xp11.4. A, Segregation of the duplication in the two families with dupli-
cation of the TM4SF2 gene. B. Genomic quantitative PCR of Family 8 using eight probes across the TM4SF2 gene; similar results 
were obtained in Family 7 (not shown).BMC Medical Genomics 2008, 1:50 http://www.biomedcentral.com/1755-8794/1/50
Page 8 of 14
(page number not for citation purposes)
trols, making it very unlikely that the duplication plays a
pathogenic role in CI and/or ASD.
Copy number variations in PAR1
Sixteen unrelated ASD subjects (5.4%) were found to have
an apparent duplication for the probe in exon 8 of the
ASMT gene, which localizes at the end of the PAR1 region.
All other probes in the PAR1 region (targeting the SHOX,
CSF2RA and IL3RA genes) showed normal gene dosage.
To both validate and map the duplication, Q-PCR probes
and assays were designed to across the interval, targeting
both neighbouring or overlapping genes (ASMTL, P2RY8,
and CXYorf3) as well as additional ASMT exons. Q-PCR
revealed that the duplication includes a ~18 kb fragment
spanning exon 2 to exon 8 of the ASMT gene (Figure 4).
To ensure that the observed duplication was not due to
copy number artefacts arising in transformed lymphoblas-
toid cell lines, blood DNA from an additional 30 unre-
lated subjects with ASD were further screened, and the
duplication was found in 2 such cases (6.7%).
Screening of 248 Caucasian controls identified 4 such
duplications (1.6%), reflecting a significant increase in
ASD as compared to controls. Comparing the Caucasian
cases in the first screen (n = 222) with the Caucasian con-
trols (n = 248) demonstrated significant differences
(Fisher Exact test P = 0.003). Furthermore, four subjects
with ASD showed four copies of the duplicated region,
which were not observed in any controls. In every case
where it could be determined in the ASD families, segre-
gation analysis showed that the duplication was transmit-
ted (9 cases from the mother, 7 from the father, with the
remaining samples missing at least one parent). ADI-R
scores were available in thirteen families [see Additional
file 3].
Apparent copy number variations due to altered probe 
binding
In three cases, apparent deletions identified by MLPA were
subsequently shown to be single-base changes that altered
the binding of the MLPA probes. Eight probes were
screened in the 11p13 region associated with WAGR syn-
drome, in BDNF (2 probes), PAX6 (3 probes), WT1 (2
probes) and HIPK3 (1 probe). An apparent deletion of a
single probe in PAX6 was observed in an affected boy, and
in his affected brother and sister (all with a diagnosis of
autism). The apparent deletion was paternally derived.
Sequencing of the region to which the MLPA probes
bound demonstrated a synonymous single base change
(c.545 C→T) in exon 5 in all individuals with the appar-
ent deletion, indicating that reduced binding of the probe
was the cause for the apparent deletion. This rare variant
hasn't been previously described.
Six probes were screened in the 8q24 region associated
with Langer-Giedion syndrome, in TRPS1  (2 probes),
EIF3S3  (1 probe), EXT1  (2 probes) and SAMD12  (1
probe). An apparent deletion of a single probe in EXT1
gene was observed in an affected boy, in one of his broth-
ers with autism, and in two of three unaffected siblings.
Quantitative PCR mapping for the ASMT gene duplication Figure 4
Quantitative PCR mapping for the ASMT gene duplication. Quantitative PCR probes were designed to detect copy 
number changes in ASMTL, P2RY8, CXYorf3 (which overlaps with exon 1 of ASMT), and ASMT (exons 1, 2, 3, 6, 8, 9, and 10). 
Results for a normal control (white), a subject with ASD but without the duplication (green), a subject with ASD with the 
duplication (i.e., three copies) (blue), and a subject with ASD with four copies of the region (red) are shown.BMC Medical Genomics 2008, 1:50 http://www.biomedcentral.com/1755-8794/1/50
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Neither parent showed the apparent deletion; however,
microsatellite analysis confirmed maternity but not pater-
nity. Sequencing the probe binding region identified a
c.3089 C→G change in 3' UTR of the EXT1 gene, which
segregated with the altered binding of the MLPA probe
and hasn't been previously described.
An apparent deletion for a probe in exon 9 of ARHGEF6
on Xq26 was found in a boy with autism. MLPA probes in
exon 1, exon 4 and exon 18 showed normal dosage. The
apparent deletion was maternally derived, and was also
found in an affected brother. Sequencing of exon 9 iden-
tified a synonymous single base change (c.1404 C→T) not
described previously in the region of probe binding that
segregated with the altered MLPA results.
Discussion
In this study, 279 unrelated subjects with ASDs were
investigated for microdeletions and microduplications
associated with CI using MLPA. The cohort was ascer-
tained for genetic studies with exclusion criteria including
a prior medical diagnosis. Two hundred and fifty-four of
the subjects screened were from multiplex families. We
made use of four commercial MLPA probe kits, which cap-
tured many of the microdeletions and microduplications
previously associated with CI and, in some cases, with
ASDs. A focus on known microdeletions and microdupli-
cations makes the results most relevant to genetic counsel-
ling. In general, our study found ~1–2% of the cases had
a chromosomal abnormality previously associated with
CI. This yield suggests that directed MLPA, expanded to
include additional ASD loci, would represent one option
for clinical testing as the cost is substantially smaller than
genome-wide arrays. Of course, additional methods will
be required for the detection of point mutations in the rel-
evant genes as MLPA will not readily detect point muta-
tions.
We identified 4 duplications in chromosome 15, two typ-
ical and two atypical. Chromosome 15q11-q13 duplica-
tions are the most common alteration in autism in prior
studies [11,27-30]. The most frequently reported pattern
of 15q11-q13 duplications in autism is supernumerary
marker chromosome 15 or isodicentric 15 [idic(15)], with
two or more extra copies of this region including the PWA
critical region and variable in size [28,29]. In this study,
we did not find any individuals with this type of duplica-
tion, probably because these abnormalities are identified
by karyotyping, and such individuals would have been
excluded in the cohort. All four duplications we found
were interstitial microduplications. The extent of these
four duplications was confirmed by dense MLPA probes.
Two of these duplications corresponded to the well-
defined duplication covering the PWA critical region
between breakpoints 1 and 3 and have been reported in
many individuals with autism or ASD [24,25]. This region
is subject to imprinting and maternal duplications are
associated with ASD, while paternal duplications usually
have a normal phenotype [30]. The two novel 15q11-q13
duplications were situated on each side of PWA critical
region, on 15q11.2 and 15q12, respectively.
One of the novel duplications (proband 3) is ~1 Mb in
size adjacent to the UBE3A gene, which is the gene respon-
sible for Angelman syndrome. The duplication encom-
passes two potential autism susceptibility genes, GABRB3
and ATP10A. Several association studies have suggested
that GABRB3 could be an autism susceptibility gene [31-
33]. For example, we and others previously reported that
there is a significant association between a polymorphism
of the GABRB3 gene and ASD (and see discussion therein)
[33]. Another group reported GABRB3  associated with
ASD and found evidence for linkage in a subgroup of
patients with an elevated score on the "insistence on
sameness" factor [34]. A recent functional study using
ASD brain samples demonstrated that GABRB3 is subject
to epigenetic dysregulation: the product of the MECP2
gene, which when mutated can cause Rett syndrome,
binds to methylated CpG sites within GABRB3 and acts as
a chromatin organizer for optimal expression of both alle-
les of GABRB3 in neurons [35]. ATP10A is a P-type ATPase
gene maternally expressed. A linkage disequilibrium study
in the 15q11-q13 region found preferential transmission
of a haplotype of ATP10A to ASD subjects [36]. The de
novo origin of this duplication in patient 3 is consistent
with a potentially causal role in ASD.
Another novel small duplication (proband 4) was located
adjacent to SNRPN, a gene implicated in Prader-Willi syn-
drome (PWS). Three small genes, MKRN3, MAGEL2 and
NDN, are situated within this very circumscribed region.
MKRN3  codes a ring finger protein while NDN  and
MAGEL2 belong to the same NDN/MAGE gene family. All
three genes are expressed exclusively from the paternal
allele and are thought to be implicated in some clinical
features of PWS [37-39]. MAGEL2 is important in regulat-
ing the circadian rhythmicity related to some features of
PWS [40,41]. NDN also plays a role in facilitating the dif-
ferentiation and specification of GABAergic neurons in
cooperation with Dlx homeodomain proteins [42]. Again,
the de novo origin of the duplication in family 4 is consist-
ent with a potentially causal role in ASD.
In a recent review that diagrammed all the cytogenetic
abnormalities reported in cases of autism [11], many
cases of 15q11-q13 duplications with variable size over-
lapped our two novel duplications. Candidate genes in
these two causal regions may implicate aberrant gluta-
mate signalling interacting with epigenetic factors in some
ASD cases. However, segregation studies complicate sim-BMC Medical Genomics 2008, 1:50 http://www.biomedcentral.com/1755-8794/1/50
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ple explanations of causality. In Family 3, the small dupli-
cation of ATP10A and GABRB3 was found in one affected
male proband but not in his affected sister, whereas in
Family 4 the duplication of MKRN3, MAGEL2 and NDN
was found in the affected monozygotic twins. However, it
is again important to note that both of the novel duplica-
tions arose de novo, providing support for a causal or con-
tributory role for these genomic variants to ASD.
However, the mechanism by which these novel duplica-
tions may contribute to ASD needs further analyses.
Two subjects with a 22q11.2 duplication cognate to the
22q11 deletion syndrome or DiGeorge syndrome were
observed. Several studies reported a high rate (20%–50%)
of autistic spectrum disorders in children with 22q11.2
deletion syndrome [43-45]. Recently, the 22q11.2 dupli-
cation was found as a highly variable syndrome [26,46].
The majority of patients with 22q11 duplications have
cognitive deficits including speech delay and develop-
mental delay, although the penetrance is variable [47].
The 22q11 duplication was also associated with variable
presentation in our study. The duplication was found in a
male proband with autism but not in an affected brother
with broad-spectrum disorder in one case, while it was
present in a female proband with autism but not in her
autistic brother in the second case. In Family 5, the report-
edly healthy father was found as a carrier of duplication.
Phenotypically normal parents of 22q11.2 duplication
children also were reported in other studies as carriers of
this duplication [26]. Notably, in Family 5, the duplica-
tion was associated with a more severe phenotype (nar-
row autism versus board spectrum disorder), while in
Family 6, a girl (perhaps with a higher threshold for liabil-
ity) carried the duplication but her autistic brother did
not. It is widely recognized that deletion of 22q11 region
is related to CI and psychiatric symptoms, including
delayed motor and speech-language development, mental
retardation, impaired spatial reasoning, attention-deficit
hyperactivity disorder, autism spectrum disorders, mood
disorders, and/or schizophrenia spectrum disorders
[48,49]. Multiple genes within this causal region have
been identified playing a role in neuronal cognitive devel-
opment [50-52], with TBX1 implicated in ASD [52]. Thus,
the 22q11.2 duplication might also function as a risk fac-
tor for ASD and increase the liability or severity in ASD
individuals.
ASDs can share characteristics with Williams-Beuren syn-
drome and a recent study of 128 children with WBS iden-
tified nine with ASD [53,54]. Duplications of the WBS
critical region in 7q11.23 have also been described in sev-
eral patients with ASD, severe language delay and mental
retardation [55]. Another study reported a case with a
diagnosis of ASD and an atypical deletion of WBS interval
[56]. Similarly, a 17p11 deletion can cause Smith-
Magenis syndrome, and 17p11 duplication is now recog-
nized as a new syndrome of mental retardation, often
associated with autistic features [57,58]. We did not
observe any deletion/duplication in these regions in our
sample, suggesting that these gene dosage anomalies are
rare contributors to ASDs.
One subject and his monozygotic twin were found to be
partially deleted for one allele of aspartoacylase (ASPA)
gene, while the second allele was intact. Mutations of
ASPA gene cause Canavan disease [MIM608034], an auto-
somal recessive disorder. Both subjects in our study have
a diagnosis of autism, and their mother, determined as
unaffected, also carries this deletion. We assume that this
deletion is not associated with the ASD phenotype.
Fragile X syndrome is the most common syndrome
related to ASD. The prevalence of autism or autistic fea-
tures in individuals with fragile syndrome is about 25–
33%, and the prevalence of fragile X in autism is estimated
at 2% [8,9]. Fragile X is a single-gene disorder typically
caused by inactivation of the FMR1 gene at Xq28 typically
by trinucleotide repeat expansion. In our study, no gene
dosage abnormality was found in FMR1 and FMR2, but
note that expansions would not be detected by MLPA.
In addition to the FMR genes, other genes related to X-
linked mental retardation were screened in this study.
TM4SF2 or tetraspanin 7 (TSPAN7) at Xp11.4 was found
partially duplicated in two unrelated subjects with autism
in our sample. Q-PCR confirmed that the duplication
included exons 2 to the down stream of TM4SF2 gene, but
not exon 1. Probes of PQBP1  gene on Xp11.23, and
probes of ARX, IL1RAPL1 and RPS6KA3 genes on Xp22
showed normal dosage. This indicates that a microdupli-
cation exists in Xp11 with a breakpoint within the
TM4SF2 gene. The protein encoded by the TM4SF2 gene
mediates signal transduction events that play a role in the
regulation of cell development, activation, growth and
motility [59]. It is known to form a complex with integrins
[60], and two integrin genes, integrin beta 3 (ITGB3) and
integrin beta 4 (ITGB4), were reported associated with
ASDs [61,62]. There is some evidence for a role for
TM4SF2 in mental retardation. The first study identified a
translocation in this gene in a female patient with mild
mental retardation associated with minor autistic features,
as well as mutations (a premature stop codon and a mis-
sense mutation, both maternally inherited) in 2 out of 33
small families with X-linked mental retardation [60].
Note, however, that a subsequent study questioned the
role of the gene and particularly one of the missense
mutations (P172H) identified in the first study, because
further linkage analysis based on cognitive status
appeared to exclude the region of the TM4SF2 gene [63].
However, this same variant has subsequently beenBMC Medical Genomics 2008, 1:50 http://www.biomedcentral.com/1755-8794/1/50
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observed in an additional individual with mental retarda-
tion [64], but not in 320 controls with similar ethnic
background. An additional deletion in the gene has also
been identified in mental retardation [65]. A recent study
reported TM4SF2 duplication in two patients, one with
syndromic and the other with nonsyndromic mental
retardation [66], but suggested that this duplication might
be a neutral polymorphism as there was no evidence for
skewed X-chromosome inactivation in the unaffected
mothers carrying the duplication. We have now identified
this same duplication in both male and female
unscreened control subjects, supporting the interpretation
that this duplication is a neutral polymorphism.
In individuals with Klinefelter syndrome (47, XXY), levels
of ASD traits are significantly higher across all dimensions
of the phenotype, which suggests that gene dosage
changes on X chromosome might play a role in ASD
behaviours [10,67]. Similarly, individuals with an XYY
karyotype have been reported to have delayed speech and
language skills or ASD [68]. The pseudoautosomal
regions (PAR1 and PAR2) are homologous across the X
and Y chromosomes. Deletions of these regions have been
reported in three females with ASD [69]. In addition, the
gene for acetyserotonin O-methyltransferase (ASMT),
located in PAR1, has been reported to be associated with
abnormal melatonin synthesis in ASD [70,71].
The PAR1 and PAR2 regions are not well-represented in
some arrays used for genome-wide studies and our MLPA
results represent the first extensive analysis of these
regions in ASD. We found a duplication in the ASMT gene
to be significantly associated with ASD in the current sam-
ple. Follow-up genetic studies in additional cohorts
would be worthwhile to confirm our finding. Further
studies on genetic variation in the ASMT gene, the effects
of the CNV on gene expression, and the relationship of
this CNV to both ASDs and sleep disorders are warranted.
Finally, our study showed that MLPA can be a useful, inex-
pensive tool to evaluate clinically significant chromo-
somal microdeletions and microduplications in ASD and
associated disorders. It is likely that with a targeted panel
of MLPA probes, clinical genetic diagnoses can now be
made in over 10% of ASDs cases. MLPA is considerably
less expensive when compared to FISH and to aCGH-
based method; and it can be efficient even when com-
pared to Q-PCR. MLPA is also an accepted approach in
New York State (NYS), which has not yet approved large-
scale aCGH-based tests. MLPA can also be used to validate
aCGH or microarray findings.
We have identified one limitation of MLPA, in that there
can be a loss of signal in the case of a single base change
within a probe-binding site. In the current study, three
apparent deletions were later identified to be caused by
single-base sequence changes in probe binding regions,
indicating that MLPA results indicating a potential dele-
tion in a single probe should be followed-up by addi-
tional studies. Although none of these variants that we
identified were observed in 49 Caucasian controls (data
not shown) (nor were they found in the NCBI SNP data-
base), the variants were non coding (two, in PAX6 and
ARHGEF6 resulted synonymous amino acid changes, and
one was located in the 3' UTR of EXT1), and are variants
of unknown significance.
Conclusion
In summary, we used MLPA as a screen and identified
known and novel chromosomal abnormalities in ASD.
We observed instances of microduplications in 15q11-
q13, including two novel microduplications, and micro-
duplications in 22q11.2. We also identified duplications
in ASMT, which may contribute to ASD risk or ASD-asso-
ciated traits. Compared to array based methods, MLPA,
with subsequent validation of potential deletions, is a rel-
atively practical, inexpensive and fast tool for screening
for chromosome rearrangements in ASDs. It is important
to validate deletions identified with MLPA by the use of
multiple probes and/or additional technical approaches.
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